Search

everythinglearnresearchcommunity

for

Search:↓

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.

Higher free testosterone levels can increase bone density and decrease body fat but may raise the risk of prostate cancer, hair loss, and benign prostate enlargement.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.

A new compound was made that might help treat diseases related to male hormones.

ERG increases SOX9, promoting prostate cancer growth and invasion.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.

Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Testosterone is vital for male health, and its deficiency is linked to aging and common health issues.

Testosterone may influence COVID-19 severity and outcomes.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.